ET
ETLI.XETRA L&G Pharma Breakthrough UCITS ETF
- EUR
No recent price
- Total assets
- 21.4M
- Expense ratio
- 0.51%
- Dividend yield
- 0.97%
- 1-year return
- +17.00%
- Holdings
- 10
- Since
- 2018
Fund data as reported by the issuer, updated Nov 6, 2026. Total assets are in the fund's base currency.
What does ETLI.XETRA invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (63.4%)
- Largest sector: Healthcare (101.5%)
- Largest region: North America (68.4%)
- Top 3 holdings: 8.9% of the fund
Asset allocation
- US stocks 63.4%
- Non-US stocks 33.3%
- Cash 0.1%
Top holdings
- Xeris Pharmaceuticals Inc 3.22%
- United Therapeutics Corporation 2.88%
- Ligand Pharmaceuticals Incorporated 2.81%
- Genmab A/S 2.80%
- Rigel Pharmaceuticals Inc 2.75%
L&G Pharma Breakthrough UCITS ETF performance
Sharpe ratio 0.79- This year
- +12.29%
- 1 year
- +17.00%
- 3 years
- +15.98%
- 5 years
- +2.46%
Volatility 15.8% over 1 year and 15.3% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
ETLI.XETRA price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
L&G Pharma Breakthrough UCITS ETF top holdings
27.8% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Xeris Pharmaceuticals Inc XERS.US | Healthcare | United States | 3.22% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 2.88% |
| Ligand Pharmaceuticals Incorporated LGND.US | Healthcare | United States | 2.81% |
| Genmab A/S GMAB.CO | Healthcare | Denmark | 2.80% |
| Rigel Pharmaceuticals Inc RIGL.US | Healthcare | United States | 2.75% |
| LG Chemicals 051910.KQ | - | Korea | 2.74% |
| Basilea Pharmaceutica AG BSLN.SW | Healthcare | Switzerland | 2.70% |
| Halozyme Therapeutics Inc HALO.US | Healthcare | United States | 2.68% |
| Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI | Healthcare | Italy | 2.68% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.54% |
ETLI.XETRA sector exposure
- Healthcare101.5%
- Basic Materials2.2%
Share of the stocks in the fund.
ETLI.XETRA regional exposure
- North America68.4%
- Europe Developed16.2%
- Japan10.2%
- United Kingdom3.0%
- Asia Developed2.2%
- Asia Emerging1.9%
Share of the stocks in the fund.
Company size
Average market cap 10.7B- Mega cap5.6%
- Big cap13.8%
- Medium cap32.3%
- Small cap26.6%
- Micro cap20.9%
L&G Pharma Breakthrough UCITS ETF fund profile
- Fund name
- L&G Pharma Breakthrough UCITS ETF
- Ticker
- ETLI.XETRA
- Exchange
- XETRA Stock Exchange
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Jan 18, 2018
- Trading currency
- EUR
- Expense ratio
- 0.51%